JP Morgan Chase
HEPA

JP Morgan Chase’s Hepion Pharmaceuticals HEPA Stock Holding History

JP Morgan Chase’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Hold
0
– -$27 – 7534
2024
Q1 		– Sell
-22
Closed -$2.53K – 7128
2023
Q4 		$3.61K Buy
+22
New +$4.16K ﹤0.01% 6618
2023
Q3 		– Hold
0
– – – 7122
2020
Q1 		– Hold
0
– – – 5458
2019
Q4 		– Hold
0
– – – 5725
2019
Q3 		– Hold
0
– – – 5827
2019
Q2 		– Hold
0
– – – 5852
2019
Q1 		– Hold
0
– – – 5884
2018
Q4 		– Hold
0
– – – 5776
2018
Q3 		– Hold
0
– – – 5468
2018
Q2 		– Hold
0
– – – 5206
2018
Q1 		– Hold
0
– – – 4846
2017
Q4 		– Hold
0
– – – 4777
2017
Q3 		– Hold
0
– – – 4289
2017
Q2 		– Hold
0
– – – 4131
2017
Q1 		– Hold
0
– – – 3846
2016
Q4 		– Hold
0
– – – 4097
2016
Q3 		– Hold
0
– – – 4649
2016
Q2 		– Hold
0
– – – 4859
2016
Q1 		– Hold
0
– -$1K – 4786
2015
Q4 		– Hold
0
– – – 4595

Other funds holding HEPA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase's HEPA Position: Q2 2024 in Review

JP Morgan Chase held its Hepion Pharmaceuticals (HEPA) position steady in Q2 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7534.

JP Morgan Chase first reported a position in HEPA in Q4 2023 and has held it in 1 quarter since. The position peaked at $3.61K in Q4 2023. 18 funds tracked by Wall St. Rank hold HEPA as of Q2 2024.

  • JP Morgan Chase held 0 shares of Hepion Pharmaceuticals worth $0 as of Q2 2024.
  • JP Morgan Chase left its Hepion Pharmaceuticals share count unchanged in Q2 2024.
  • Hepion Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2024, its #7534 holding.
  • JP Morgan Chase first reported a position in Hepion Pharmaceuticals in Q4 2023 and has held it in 1 quarter since.
  • JP Morgan Chase's Hepion Pharmaceuticals position peaked at $3.61K in Q4 2023.
  • 18 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.